EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Lina Camacho-Arteaga, Gloria Iacoboni, Mi Kwon, Rebeca Bailén, Rafael Hernani, Ana Benzaquén, Lucía López-Corral, Estefania Pérez-López, Lina María Leguízamo-Martínez, Maria Calvo-Orteu, Manuel Guerreiro, Aitana Balaguer-Rosello und 4 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2024.61683 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Lina Camacho-Arteaga und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Acute adverse events (AEs) after chimeric antigen receptor (CAR) T-cell infusion are well documented, but less information is available regarding the long-term toxic effects.

Objective

To assess the occurrence of late AEs for adult patients with large B-cell lymphoma (LBCL) treated with commercially available CD19-targeted CAR T cells. Design, Setting, and Participants A prospective, observational, clinical practice cohort study was conducted from September 1, 2018, to December 31, 2022, among 172 adult patients in 6 Spanish hospitals who received CD19-targeted CAR T-cell therapy for relapsed or refractory LBCL and survived at least 3 months after infusion, without subsequent antilymphoma therapy. Exposure Treatment with tisagenlecleucel or axicabtagene ciloleucel. Main Outcomes and Measures Data on any late AEs occurring in this patient population were collected until the patients received new antilymphoma therapy, were lost to follow-up, died, or reached 24 months after infusion, whichever occurred first. Data collection for each patient started at the third month after infusion and included new-onset AEs, as well as persistent AEs that started earlier but were still ongoing at that time point.

Results

The study enrolled 172 patients (mean [SD] age, 58.5 [13.7] years; 101 men [58.7%]), of whom 135 (78.5%) experienced at least 1 late AE of any grade. Infections were the late AEs with the highest incidence (5.6 per 100 person-months [95% CI, 4.5-7.0 per 100 person-months]), followed by neutropenia (3.6 per 100 person-months [95% CI, 2.9-4.5 per 100 person-months]) and thrombocytopenia (2.2 per 100 person-months [95% CI, 1.7-3.0 per 100 person-months]). The incidence of infectious episodes remained stable during the whole study period, while cytopenias decreased beyond 6 months after infusion. All cases of nonrelapse-related mortality were due to infections (COVID-19 pneumonia in 3 patients and sepsis or bacterial pneumonia in 4 patients). Twenty-three patients (13.4%) experienced 27 dermatologic AEs, all mild, with most of them (88.9% [24 of 27]) starting beyond 3 months after infusion. Fifteen neurologic AEs were reported in 15 patients (8.7%), and 10 patients (5.8%) developed 13 cardiovascular AEs. Five secondary neoplasms were reported in 4 patients (2.3%), with no cases of T-cell malignant neoplasms. Conclusions and Relevance This cohort study suggests that CAR T-cell therapy has a favorable safety profile. However, continuous follow-up of patients is needed, as serious AEs can occur years after infusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedProspective StudiesAgedAdultSpainAntigens, CD19Receptors, Antigen, T-CellBiological Products

Substanzen

axicabtagene ciloleuceltisagenlecleucelReceptors, Chimeric AntigenAntigens, CD19Receptors, Antigen, T-CellBiological Products

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Clinical Pharmacology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.

Zitieren

APA

Camacho-Arteaga, L., Iacoboni, G., Kwon, M., Bailén, R., Hernani, R., Benzaquén, A., López-Corral, L., Pérez-López, E., Leguízamo-Martínez, L. M., Calvo-Orteu, M., Guerreiro, M., Balaguer-Rosello, A., Alonso-Martínez, C., Vidal, X., Barba, P., & Agustí, A. (2025). Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.61683

Vancouver

Camacho-Arteaga L, Iacoboni G, Kwon M, Bailén R, Hernani R, Benzaquén A, et al. Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2024.61683

BibTeX
@article{CamachoArteaga2025,
  author = {Camacho-Arteaga, Lina and Iacoboni, Gloria and Kwon, Mi and Bailén, Rebeca and Hernani, Rafael and Benzaquén, Ana and López-Corral, Lucía and Pérez-López, Estefania and Leguízamo-Martínez, Lina María and Calvo-Orteu, Maria and Guerreiro, Manuel and Balaguer-Rosello, Aitana and Alonso-Martínez, Carla and Vidal, Xavier and Barba, Pere and Agustí, Antònia},
  title = {Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2024.61683}
}
Kostenlos starten →